event,time
66 years old ,0
    woman ,0
    presented with fever ,-192
    fever ,-192
    close contact with confirmed COVID-19 case ,-192
    SARS-CoV-2 RNA detected ,-192
    initial supportive treatment ,-192
    fever ,-192
    headache ,0
    fatigue ,0
    muscle aches ,0
    mild abdominal pain ,0
    diarrhoea ,0
    vomiting ,0
    presented to hospital ,0
    hypertension ,0
    osteopenia ,0
    Perindopril/Amlodipine ,0
    Cholecalciferol ,0
    ex-smoker ,0
    20 pack years ,0
    no history of immunosuppression ,0
    no chronic organ dysfunction ,0
    no history of fungal colonization ,0
    independent in activities of daily living ,0
    fever (40°C) ,0
    respiratory rate 26/min ,0
    pulse 80/min ,0
    blood pressure 120/70 mmHg ,0
    oxygen saturation 89% on room air ,0
    increase in work of breathing ,0
    bibasal coarse crepitations ,0
    arterial blood gas ,0
    pH 7.44 ,0
    PaO2 70 mmHg ,0
    PaCO2 34 mmHg ,0
    lactate 0.9 mmol/L ,0
    white blood cell count 5.3 ×109/L ,0
    neutrophil differential count 3.9 ×109/L ,0
    lymphocyte count 1.2 ×109/L ,0
    AST 52U/L ,0
    ALT 32 U/L ,0
    GGT 61U/L ,0
    LDH 429 U/L ,0
    normal renal function ,0
    blood cultures isolated Facklamia hominis ,0
    urine culture isolated Escherichia coli ,0
    susceptible to Ceftriaxone ,0
    chest radiology demonstrated pulmonary opacities ,0
    admitted to COVID-19 respiratory ward ,0
    Ceftriaxone 1g daily ,0
    Azithromycin 500mg daily ,0
    supplemental oxygen ,0
    subcutaneous enoxaparin sodium ,0
    no specific COVID-19 therapy ,0
    condition deteriorated ,24
    progressive dyspnoea ,24
    increasing oxygen requirement ,24
    admitted to ICU ,24
    temperature 39.5°C ,24
    respiratory rate 40/min ,24
    oxygen saturation 91% on HFNP ,24
    FiO2 40% ,24
    airflow 40 L/m ,24
    no heart failure signs ,24
    echocardiogram demonstrated normal biventricular function ,24
    mild right ventricular dilatation ,24
    arterial blood gas on FiO2 40% ,24
    pH 7.46 ,24
    PaO2 59 mmHg ,24
    PaCO2 31 mmHg ,24
    awake prone positioning ,24
    no improvement in oxygenation ,24
    endotracheal intubation ,24
    mechanical ventilation ,24
    lung-protective ventilation ,24
    deterioration in ventilatory parameters ,24
    severe ARDS criteria ,24
    worsening respiratory function ,192
    hypercapnoea ,192
    fever absent ,192
    CRP 351mg/L ,192
    ALT 125 U/L ,192
    AST 154 U/L ,192
    GGT 611 U/L ,192
    ALP 229 U/L ,192
    ferritin 1295 μg/L ,192
    D-dimer 0.99mg/L ,192
    fibrinogen 5.8g/L ,192
    chest radiology progression ,192
    ETT sample obtained ,192
    SARS-CoV-2 RNA persistent ,192
    7-day Piperacillin/Tazobactam ,192
    prone ventilation ,192
    improvement in ventilatory parameters ,192
    fungal elements on Gram stain ,192
    Aspergillus fumigatus complex isolated ,192
    three subsequent ETT cultures isolated Aspergillus ,192
    new onset fever ,240
    bilateral consolidation ,240
    intravenous Voriconazole initiated ,240
    fever settled ,264
    inflammatory markers improved ,264
    liver function normalized ,264
    Voriconazole trough levels 2.72mg/L ,264
    extubated ,288
    oral Voriconazole 300mg twice daily ,288
    two negative SARS-CoV-2 RT-PCR ,360
    discharged home ,360
    CECT chest ,432
    bilateral organising pneumonia ,432
    fibrosis ,432
    segmental pulmonary embolism ,432
    Voriconazole ceased ,432
    Apixaban ,432
    liver function testing ,432
    Voriconazole trough level 3.6mg/L ,432
    mild dry cough ,432
    improved effort tolerance ,432
    no systemic features ,432
